lansoprazole
Sign in to saveLansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid. It is a proton pump inhibitor (PPI), used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. Its effectiveness is similar to that of other PPIs. It is taken by mouth. Onset is over a few hours and effects last up to a couple of days.
Key facts
- Drug.ATC_suffix
- BC03
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458267412
- Drug.image
- Lansoprazole.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 245
- Drug.image2
- Lansoprazole_3D_Xtal_Ball-and-Stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 250
- Drug.chirality
- Racemic mixture
- Drug.tradename
- Prevacid, others
- Drug.MedlinePlus
- a695020
- Drug.DailyMedID
- Lansoprazole
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.class
- Proton pump inhibitor
- Drug.ATC_prefix
- A02
- Drug.legal_AU
- S2, S3, & S4
via Wikipedia infobox
Research
3,483 papers- Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.Gastroenterology · 2023
- Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024
- Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database.The Journal of infection · 2024
- Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.Gut · 2020
- Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2016
via PubMed
Article
10 sectionsContents
- Medical uses
- Side effects
- Interactions
- Chemistry
- History
- Society and culture
- Patents
- Availability
- Research
- References
{{Infobox drug | Watchedfields = changed | verifiedrevid = 458267412 | image = Lansoprazole.svg | image_class = skin-invert-image | width = 245 | alt = | image2 = Lansoprazole_3D_Xtal_Ball-and-Stick.png | image_class2 = bg-transparent | width2 = 250 | alt2 = | caption = | chirality = Racemic mixture
| pronounce = | tradename = Prevacid, others | Drugs.com = | MedlinePlus = a695020 | DailyMedID = Lansoprazole | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth, intravenous | class = Proton pump inhibitor | ATCvet = | ATC_prefix = A02 | ATC_suffix = BC03 | ATC_supplemental = | legal_AU = S2, S3, & S4 | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = OTC | legal_US_comment = /Rx-only | legal_EU = | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status =
Gallery (2)
Connections
Categories
BenzimidazolesCYP2C19 inhibitorsDrugboxes which contain changes to watched fieldsDrugs developed by AbbVieDrugs developed by GSK plcDrugs developed by NovartisDrugs developed by Takeda Pharmaceutical CompanyDrugs with non-standard legal statusECHA InfoCard ID from WikidataOrganofluoridesOver-the-counter drugs in the United StatesPhenol ethers